-
Something wrong with this record ?
Synthesis and Spectrum of Biological Activities of Novel N-arylcinnamamides
S. Pospisilova, J. Kos, H. Michnova, I. Kapustikova, T. Strharsky, M. Oravec, AM. Moricz, J. Bakonyi, T. Kauerova, P. Kollar, A. Cizek, J. Jampilek,
Language English Country Switzerland
Document type Journal Article
NLK
Free Medical Journals
from 2000
Freely Accessible Science Journals
from 2000
PubMed Central
from 2007
Europe PubMed Central
from 2007
ProQuest Central
from 2000-03-01
Open Access Digital Library
from 2000-01-01
Open Access Digital Library
from 2007-01-01
Health & Medicine (ProQuest)
from 2000-03-01
ROAD: Directory of Open Access Scholarly Resources
from 2000
PubMed
30087309
DOI
10.3390/ijms19082318
Knihovny.cz E-resources
- MeSH
- Anti-Bacterial Agents chemical synthesis chemistry pharmacology MeSH
- Antifungal Agents chemical synthesis chemistry pharmacology MeSH
- Antitubercular Agents chemical synthesis chemistry pharmacology MeSH
- Biofilms drug effects MeSH
- Cinnamates chemical synthesis chemistry pharmacology MeSH
- Fusarium drug effects MeSH
- Humans MeSH
- Methicillin-Resistant Staphylococcus aureus drug effects physiology MeSH
- Microbial Sensitivity Tests MeSH
- Mycobacterium tuberculosis drug effects physiology MeSH
- Plant Diseases microbiology MeSH
- Plants microbiology MeSH
- Staphylococcal Infections drug therapy MeSH
- Staphylococcus aureus drug effects physiology MeSH
- Chemistry Techniques, Synthetic MeSH
- Tuberculosis drug therapy MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
: A series of sixteen ring-substituted N-arylcinnamamides was prepared and characterized. Primary in vitro screening of all the synthesized compounds was performed against Staphylococcus aureus, three methicillin-resistant S. aureus strains, Mycobacterium tuberculosis H37Ra, Fusarium avenaceum, and Bipolaris sorokiniana. Several of the tested compounds showed antistaphylococcal, antitubercular, and antifungal activities comparable with or higher than those of ampicillin, isoniazid, and benomyl. (2E)-N-[3,5-bis(trifluoromethyl)phenyl]-3-phenylprop-2-enamide and (2E)-3-phenyl-N-[3-(trifluoromethyl)phenyl]prop-2-enamide showed the highest activities (MICs = 22.27 and 27.47 µM, respectively) against all four staphylococcal strains and against M.tuberculosis. These compounds showed an activity against biofilm formation of S.aureus ATCC 29213 in concentrations close to MICs and an ability to increase the activity of clinically used antibiotics with different mechanisms of action (vancomycin, ciprofloxacin, and tetracycline). In time-kill studies, a decrease of CFU/mL of >99% after 8 h from the beginning of incubation was observed. (2E)-N-(3,5-Dichlorophenyl)- and (2E)-N-(3,4-dichlorophenyl)-3-phenylprop-2-enamide had a MIC = 27.38 µM against M. tuberculosis, while a significant decrease (22.65%) of mycobacterial cell metabolism determined by the MTT assay was observed for the 3,5-dichlorophenyl derivative. (2E)-N-(3-Fluorophenyl)- and (2E)-N-(3-methylphenyl)-3-phenylprop-2-enamide exhibited MICs = 16.58 and 33.71 µM, respectively, against B. sorokiniana. The screening of the cytotoxicity of the most effective antimicrobial compounds was performed using THP-1 cells, and these chosen compounds did not shown any significant lethal effect. The compounds were also evaluated for their activity related to the inhibition of photosynthetic electron transport (PET) in spinach (Spinacia oleracea L.) chloroplasts. (2E)-N-(3,5-dichlorophenyl)-3-phenylprop-2-enamide (IC50 = 5.1 µM) was the most active PET inhibitor. Compounds with fungicide potency did not show any in vivo toxicity against Nicotiana tabacum var. Samsun. The structure⁻activity relationships are discussed.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19000485
- 003
- CZ-PrNML
- 005
- 20190107104313.0
- 007
- ta
- 008
- 190107s2018 sz f 000 0|eng||
- 024 7_
- $a 10.3390/ijms19082318 $2 doi
- 035 __
- $a (PubMed)30087309
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Pospisilova, Sarka $u Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Comenius University, Odbojarov 10, 83232 Bratislava, Slovakia. sharka.pospisilova@gmail.com. Department of Infectious Diseases and Microbiology, Faculty of Veterinary Medicine, University of Veterinary and Pharmaceutical Sciences, Palackeho 1, 61242 Brno, Czech Republic. sharka.pospisilova@gmail.com.
- 245 10
- $a Synthesis and Spectrum of Biological Activities of Novel N-arylcinnamamides / $c S. Pospisilova, J. Kos, H. Michnova, I. Kapustikova, T. Strharsky, M. Oravec, AM. Moricz, J. Bakonyi, T. Kauerova, P. Kollar, A. Cizek, J. Jampilek,
- 520 9_
- $a : A series of sixteen ring-substituted N-arylcinnamamides was prepared and characterized. Primary in vitro screening of all the synthesized compounds was performed against Staphylococcus aureus, three methicillin-resistant S. aureus strains, Mycobacterium tuberculosis H37Ra, Fusarium avenaceum, and Bipolaris sorokiniana. Several of the tested compounds showed antistaphylococcal, antitubercular, and antifungal activities comparable with or higher than those of ampicillin, isoniazid, and benomyl. (2E)-N-[3,5-bis(trifluoromethyl)phenyl]-3-phenylprop-2-enamide and (2E)-3-phenyl-N-[3-(trifluoromethyl)phenyl]prop-2-enamide showed the highest activities (MICs = 22.27 and 27.47 µM, respectively) against all four staphylococcal strains and against M.tuberculosis. These compounds showed an activity against biofilm formation of S.aureus ATCC 29213 in concentrations close to MICs and an ability to increase the activity of clinically used antibiotics with different mechanisms of action (vancomycin, ciprofloxacin, and tetracycline). In time-kill studies, a decrease of CFU/mL of >99% after 8 h from the beginning of incubation was observed. (2E)-N-(3,5-Dichlorophenyl)- and (2E)-N-(3,4-dichlorophenyl)-3-phenylprop-2-enamide had a MIC = 27.38 µM against M. tuberculosis, while a significant decrease (22.65%) of mycobacterial cell metabolism determined by the MTT assay was observed for the 3,5-dichlorophenyl derivative. (2E)-N-(3-Fluorophenyl)- and (2E)-N-(3-methylphenyl)-3-phenylprop-2-enamide exhibited MICs = 16.58 and 33.71 µM, respectively, against B. sorokiniana. The screening of the cytotoxicity of the most effective antimicrobial compounds was performed using THP-1 cells, and these chosen compounds did not shown any significant lethal effect. The compounds were also evaluated for their activity related to the inhibition of photosynthetic electron transport (PET) in spinach (Spinacia oleracea L.) chloroplasts. (2E)-N-(3,5-dichlorophenyl)-3-phenylprop-2-enamide (IC50 = 5.1 µM) was the most active PET inhibitor. Compounds with fungicide potency did not show any in vivo toxicity against Nicotiana tabacum var. Samsun. The structure⁻activity relationships are discussed.
- 650 _2
- $a antibakteriální látky $x chemická syntéza $x chemie $x farmakologie $7 D000900
- 650 _2
- $a antifungální látky $x chemická syntéza $x chemie $x farmakologie $7 D000935
- 650 _2
- $a antituberkulotika $x chemická syntéza $x chemie $x farmakologie $7 D000995
- 650 _2
- $a biofilmy $x účinky léků $7 D018441
- 650 _2
- $a techniky syntetické chemie $7 D060326
- 650 _2
- $a cinnamáty $x chemická syntéza $x chemie $x farmakologie $7 D002934
- 650 _2
- $a Fusarium $x účinky léků $7 D005670
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a methicilin rezistentní Staphylococcus aureus $x účinky léků $x fyziologie $7 D055624
- 650 _2
- $a mikrobiální testy citlivosti $7 D008826
- 650 _2
- $a Mycobacterium tuberculosis $x účinky léků $x fyziologie $7 D009169
- 650 _2
- $a nemoci rostlin $x mikrobiologie $7 D010935
- 650 _2
- $a rostliny $x mikrobiologie $7 D010944
- 650 _2
- $a stafylokokové infekce $x farmakoterapie $7 D013203
- 650 _2
- $a Staphylococcus aureus $x účinky léků $x fyziologie $7 D013211
- 650 _2
- $a tuberkulóza $x farmakoterapie $7 D014376
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Kos, Jiri $u Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Comenius University, Odbojarov 10, 83232 Bratislava, Slovakia. jirikos85@gmail.com.
- 700 1_
- $a Michnova, Hana $u Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Comenius University, Odbojarov 10, 83232 Bratislava, Slovakia. michnova.hana@gmail.com. Department of Infectious Diseases and Microbiology, Faculty of Veterinary Medicine, University of Veterinary and Pharmaceutical Sciences, Palackeho 1, 61242 Brno, Czech Republic. michnova.hana@gmail.com.
- 700 1_
- $a Kapustikova, Iva $u Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Comenius University, Odbojarov 10, 83232 Bratislava, Slovakia. kapustikova@fpharm.uniba.sk.
- 700 1_
- $a Strharsky, Tomas $u Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Comenius University, Odbojarov 10, 83232 Bratislava, Slovakia. strharsky2@uniba.sk.
- 700 1_
- $a Oravec, Michal $u Global Change Research Institute CAS, Belidla 986/4a, 60300 Brno, Czech Republic. oravec.m@czechglobe.cz.
- 700 1_
- $a Moricz, Agnes M $u Plant Protection Institute, Centre for Agricultural Research, Hungarian Academy of Sciences, Herman Otto Str. 15, 1022 Budapest, Hungary. moricz.agnes@agrar.mta.hu.
- 700 1_
- $a Bakonyi, Jozsef $u Plant Protection Institute, Centre for Agricultural Research, Hungarian Academy of Sciences, Herman Otto Str. 15, 1022 Budapest, Hungary. bakonyi.jozsef@agrar.mta.hu.
- 700 1_
- $a Kauerova, Tereza $u Department of Human Pharmacology and Toxicology, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences, Palackeho 1, 61242 Brno, Czech Republic. tereza.kauerova@gmail.com.
- 700 1_
- $a Kollar, Peter $u Department of Human Pharmacology and Toxicology, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences, Palackeho 1, 61242 Brno, Czech Republic. kollarp@vfu.cz.
- 700 1_
- $a Cizek, Alois $u Department of Infectious Diseases and Microbiology, Faculty of Veterinary Medicine, University of Veterinary and Pharmaceutical Sciences, Palackeho 1, 61242 Brno, Czech Republic. cizeka@vfu.cz.
- 700 1_
- $a Jampilek, Josef $u Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Comenius University, Odbojarov 10, 83232 Bratislava, Slovakia. josef.jampilek@gmail.com.
- 773 0_
- $w MED00176142 $t Int J Mol Sci $x 1422-0067 $g Roč. 19, č. 8 (2018), s.
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/30087309 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a
- 990 __
- $a 20190107 $b ABA008
- 999 __
- $a ok $b bmc $g 1364558 $s 1038608
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 19 $c 8 $e 20180807 $i 1422-0067 $m International journal of molecular sciences $n Int J Mol Sci $x MED00176142
- LZP __
- $a Pubmed-20190107